Literature DB >> 2204061

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

M A Kelliher1, J McLaughlin, O N Witte, N Rosenberg.   

Abstract

The v-abl gene in Abelson virus induces pre-B-cell lymphoma in mice while the BCR/ABL oncogene is associated with chronic myelogenous leukemia and some cases of acute lymphocytic leukemia in humans. Understanding the mechanisms by which these oncogenes affect various cell types has been hampered by a paucity of experimental systems that reproduce the range of biological effects associated with them. We have developed an experimental system in which murine hematopoietic stem cell populations are infected with either v-abl or BCR/ABL retroviruses and are used to reconstitute lethally irradiated mice. Irrespective of the form of activated abl, greater than 90% of the animals reconstituted with such cells develop tumors. About 50% of them develop a myeloproliferative syndrome that shares several features with the chronic phase of chronic myelogenous leukemia; the remaining animals succumb to pre-B-cell lymphomas. The myeloproliferative syndrome is characterized by large numbers of clonally derived, infected myeloid cells. This model will allow study of the mechanism by which activated abl genes affect hematopoietic precursors in chronic myelogenous leukemia. Furthermore, our results demonstrate that introduction of an activated abl gene into the appropriate target cell, not the structure of the gene, is the major determinant in myeloid cell specificity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204061      PMCID: PMC54594          DOI: 10.1073/pnas.87.17.6649

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  The molecular genetics of Philadelphia chromosome-positive leukemias.

Authors:  R Kurzrock; J U Gutterman; M Talpaz
Journal:  N Engl J Med       Date:  1988-10-13       Impact factor: 91.245

2.  Pathogenesis of Abelson-virus-induced murine leukemia.

Authors:  R Siegler; S Zajdel
Journal:  J Natl Cancer Inst       Date:  1972-01       Impact factor: 13.506

3.  Early morphological changes associated with infection by a murine nonthymic lymphatic tumor virus.

Authors:  L S Rabstein; A F Gazdar; H C Chopra; H T Abelson
Journal:  J Natl Cancer Inst       Date:  1971-03       Impact factor: 13.506

Review 4.  The viral and cellular forms of the Abelson (abl) oncogene.

Authors:  N Rosenberg; O N Witte
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

5.  Mac-1: a macrophage differentiation antigen identified by monoclonal antibody.

Authors:  T Springer; G Galfré; D S Secher; C Milstein
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

6.  Multiple steps are required for the induction of tumors by Abelson murine leukemia virus.

Authors:  P L Green; D A Kaehler; L M Bennett; R Risser
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.

Authors:  J C Young; O N Witte
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

8.  Hemopoietic lineage switch: v-raf oncogene converts Emu-myc transgenic B cells into macrophages.

Authors:  S P Klinken; W S Alexander; J M Adams
Journal:  Cell       Date:  1988-06-17       Impact factor: 41.582

9.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage.

Authors:  P J Fialkow; R J Jacobson; T Papayannopoulou
Journal:  Am J Med       Date:  1977-07       Impact factor: 4.965

10.  A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  96 in total

Review 1.  Biological consequences of the BCR/ABL fusion gene in humans and mice.

Authors:  M Y Gordon
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

Review 2.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Authors:  B J Druker; N B Lydon
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

3.  Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.

Authors:  Raphaël Beck; Rozangela Curi Pedrosa; Nicolas Dejeans; Christophe Glorieux; Philippe Levêque; Bernard Gallez; Henryk Taper; Stéphane Eeckhoudt; Laurent Knoops; Pedro Buc Calderon; Julien Verrax
Journal:  Invest New Drugs       Date:  2010-05-08       Impact factor: 3.850

Review 4.  Molecular pathways to CML stem cells.

Authors:  Kristen N Rice; Catriona H M Jamieson
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

5.  Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.

Authors:  A G Elefanty; S Cory
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

6.  Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemia.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Kenneth Dorshkind
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

7.  Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

Authors:  Samantha B Foley; Zacariah L Hildenbrand; Abigail A Soyombo; Jeffery A Magee; Yipin Wu; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

Review 8.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

9.  Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases.

Authors:  L Cohen; R Mohr; Y Y Chen; M Huang; R Kato; D Dorin; F Tamanoi; A Goga; D Afar; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.

Authors:  Francesca Palandri; Fausto Castagnetti; Giuliana Alimena; Nicoletta Testoni; Massimo Breccia; Simona Luatti; Giovanna Rege-Cambrin; Fabio Stagno; Giorgina Specchia; Bruno Martino; Luciano Levato; Serena Merante; Anna Maria Liberati; Fabrizio Pane; Giuseppe Saglio; Daniele Alberti; Giovanni Martinelli; Michele Baccarani; Gianantonio Rosti
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.